References
- Andersson K, Mattsson L-A, Rybo G, Stadberg E. Intrauterine release of levonorgestrel: a new way of adding progestogen in hormone replace-ment therapy. Am J Obstet Gynecol 1992;79: 963–7
- Raudaskoski T, Tapanainen J, Tomás E, et al. Intrauterine 10 itg and 20 itg levonorgestrel systems in postmenopausal women receiving oral oestrogen replacement therapy: clinical, endometrial and metabolic response. Br J Obstet Gynaecol 2002;109: 136–44
- Hirvonen E, Mälkönen M, Manninen V. Clinical and lipid metabolic effects of unopposed oestro-gen and two oestrogen-progestogen regimens in post-menopausal women. Maturitas 1987;9: 69–79
- Graff-Iversen S, Stensvold I, Lind-Larsen PG, Nodarse LO, Tverdal A, Urdal P. Serum lipids in postmenopausal or perimenopausal women using estrogen alone, estrogen with levonorges-trel, or estrogen with norethisterone, compared with nonusers: results from a cross sectional study in two Norwegian countries, 1985–1988. J Clin Epidemiol 1998;51: 1311–16
- Raudaskoski T, Lahti E, Kauppila A, Apaja-Sarkkinen M, Laatikainen T. Transdermal estro-gen with a levonorgestrel-releasing device for climacteric complaints: clinical and endometrial responses. Am J Obstet Gynecol 1995;172:114–19
- Lundstrom E, Wilczek B, von Palffy Z, Soderq-vist G, von Schoultz B. Mammographic breast density during hormone replacement therapy: effects of continuous combination, unopposed transdermal and low-potency estrogen regimens. Climacteric 2001;4:42–8
- Chlebowski RT, Hendrix SL, Langer RD, et al. for the WHI Investigators. Influence of estrogen plus progestin on breast cancer and mammo-graphy in healthy postmenopausal women: the Women's Health Initiative randomized con-trolled trial. J Am Med Assoc 2003;289:3243–53
- Million Women Study Collaborators. Breast cancer and hormone replacement therapy in the Million Women Study. Lancet 2003;362:419–27
- Writing Group for the Women's Health Initia-tive Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal wo-men: principal results from the Women's Health Initiative randomized controlled trial. J Am Med Assoc 2002;288:321–33
- Riphagen FR. Intrauterine application of pro-gestins in hormone replacement therapy: a review. Climacteric 2000;3:199–212
- Toivonen J, Lukkainen T, Allonen H. Protective effect of intrauterine release of levonorgestrol on pelvic infection: three years comparative experi-ence of levonorgestrol and copper-releasing intrauterine devices. Obstet Gynecol 1991;77: 261–4
- Lukkainen T, Allonen H, Haukkamaa M, Lähteenmäki P, Nilsson CJ, Toivonen J. Five years experience with a levonorgestrol-releasing IUCD. Contraception 1986;33:139–48
- Hillard T. Continuous combined oestrogen and progestogen. In Sturdee DW, Olah K, Keane D, eds. The Yearbook of Obstetrics and Gynaecology, vol 9. London: RCOG Press, 2002
- MacLennan AH, MacLennan A, Wenzel S, Chambers HM, Eckert K. Continuous low-dose oestrogen and progestogen replacement ther-apy: a randomised trial. Med J Aust 1993;159: 102–6
- Pickar JH, Bottiglioni F, Archer DF, for the Menopause Study Group. Amenorrhea fre-quency with continuous combined hormone replacement therapy: a retrospective analysis. Climacteric 1998;1:130–6
- Godsland IF. Effects of postmenopausal hor-mone replacement therapy on lipid, lipoprotein and apolipoprotein (a) concentrations: analysis of studies published from 1974-2000. Fertil Steril 2001;75:898–915
- Suhonen S, Holmström T, Allonen HO, Läh-teenmäki P. Intrauterine and subdermal progestin administration in postmenopausal hormone replacement therapy. Fertil Steril 1995;63:336–42
- Raudaskoski T, Laatikainen T, Kauppila A. Sex hormone binding globulin as an indicator of the hepatic impacts of continuous combined hor-mone replacement regimens. Maturitas 1998;29: 87–92